Home › Search by Antimicrobial › Tigecycline (GAR-936, Tigacyl)
Antimicrobial Name： Tigecycline (GAR-936, Tigacyl)
CAS Number： 220620-09-7
Type of Antibiotic： Tetracyclines
Functional Category： Antibiotic
Molecular Weight： 585.65
Mechanism of Action： Tigecycline (GAR-936, Tigacyl), a glycylcycline, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracycline and imparts certain microbiologic properties to tigecycline. Tigecycline is not affected by the two major tetracycline resistance mechanisms, ribosomal protection and efflux. Accordingly, tigecycline has demonstrated in vitro and in vivo activity against a broad spectrum of bacterial pathogens. There has been no cross resistance observed between tigecycline and other antibiotics. Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerase). In vitro studies have not demonstrated antagonism between tigecycline and other commonly used antibacterial drugs. In general, tigecycline is considered bacteriostatic.
Chemical Formula：

C29H39N5O8
Resistance Genes：

mepa-Multi antimicrobial extrusion (MATE) efflux family protein. Multidrug resistance efflux pump.

mexa-Resistance-nodulation-cell division transporter system. Multidrug resistance efflux pump.

mexb-Resistance-nodulation-cell division transporter system. Multidrug resistance efflux pump.

norm-Multi antimicrobial extrusion (MATE) efflux family protein. Multidrug resistance efflux pump.

oprm-Resistance-nodulation-cell division transporter system. Multidrug resistance efflux pump.
Comments：

Tigecycline (GAR-936, Tigacyl) is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo-β-Lactamase multidrug-resistant Enterobacteriaceae has also shown susceptibility to tigecycline.